MYUNGMOON Pharm co.,Ltd (017180.KS)
KRW 1860.0
(-0.59%)
KRW 1860.0
(-0.59%)
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2023 | 4.52 Billion KRW | -57.91% |
| 2022 | 10.57 Billion KRW | 4322.44% |
| 2021 | 345.37 Million KRW | 98.9% |
| 2020 | -19.35 Billion KRW | -167.38% |
| 2019 | -10.94 Billion KRW | -199.81% |
| 2018 | 7.05 Billion KRW | -41.18% |
| 2017 | 14.44 Billion KRW | 13.63% |
| 2016 | 13.22 Billion KRW | 306.55% |
| 2015 | -5.08 Billion KRW | -195.88% |
| 2014 | 6.03 Billion KRW | -16.44% |
| 2013 | 6.35 Billion KRW | 703.78% |
| 2012 | -2.71 Billion KRW | -109.55% |
| 2011 | 13.52 Billion KRW | 6.3% |
| 2010 | 12.61 Billion KRW | 25.93% |
| 2009 | 10.09 Billion KRW | 6.37% |
| 2008 | 9.54 Billion KRW | -12.38% |
| 2007 | 10.94 Billion KRW | 0.0% |
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2024 Q1 | -60.47 Million KRW | 105.21% |
| 2024 Q2 | 200.27 Million KRW | 477.5% |
| 2023 Q4 | -1.38 Billion KRW | -105.7% |
| 2023 FY | - KRW | -57.91% |
| 2023 Q3 | 24.28 Billion KRW | -2.61% |
| 2023 Q2 | 24.93 Billion KRW | 8.49% |
| 2023 Q1 | 22.98 Billion KRW | 725.42% |
| 2022 Q2 | 4.4 Billion KRW | 211.85% |
| 2022 FY | - KRW | 4322.44% |
| 2022 Q1 | 1.41 Billion KRW | 120.8% |
| 2022 Q4 | 2.78 Billion KRW | 28.32% |
| 2022 Q3 | 2.16 Billion KRW | -50.74% |
| 2021 Q1 | 2.11 Billion KRW | 129.13% |
| 2021 Q2 | 2.11 Billion KRW | 0.09% |
| 2021 Q4 | -6.79 Billion KRW | -583.36% |
| 2021 Q3 | 1.4 Billion KRW | -33.66% |
| 2021 FY | - KRW | 98.9% |
| 2020 FY | - KRW | -167.38% |
| 2020 Q3 | -3.44 Billion KRW | 66.03% |
| 2020 Q4 | -7.26 Billion KRW | -111.09% |
| 2020 Q2 | -10.12 Billion KRW | -304.77% |
| 2020 Q1 | -2.5 Billion KRW | 60.15% |
| 2019 Q4 | -6.27 Billion KRW | -1915.92% |
| 2019 FY | - KRW | -199.81% |
| 2019 Q3 | 345.73 Million KRW | 108.1% |
| 2019 Q2 | -4.26 Billion KRW | -928.51% |
| 2019 Q1 | 515.08 Million KRW | -81.59% |
| 2018 Q3 | 1.01 Billion KRW | -46.17% |
| 2018 FY | - KRW | -41.18% |
| 2018 Q1 | 2.21 Billion KRW | -14.05% |
| 2018 Q2 | 1.89 Billion KRW | -14.55% |
| 2018 Q4 | 2.79 Billion KRW | 174.29% |
| 2017 FY | - KRW | 13.63% |
| 2017 Q2 | 4 Billion KRW | 100.99% |
| 2017 Q3 | 1.53 Billion KRW | -61.78% |
| 2017 Q1 | 1.99 Billion KRW | -16.32% |
| 2017 Q4 | 2.57 Billion KRW | 68.56% |
| 2016 Q1 | 3.19 Billion KRW | 138.13% |
| 2016 Q4 | 2.38 Billion KRW | -10.49% |
| 2016 Q3 | 2.65 Billion KRW | -35.08% |
| 2016 Q2 | 4.09 Billion KRW | 28.17% |
| 2016 FY | - KRW | 306.55% |
| 2015 Q3 | 2.78 Billion KRW | 695.88% |
| 2015 Q1 | 120.52 Million KRW | -94.48% |
| 2015 Q4 | -8.38 Billion KRW | -400.47% |
| 2015 Q2 | -468.08 Million KRW | -488.38% |
| 2015 FY | - KRW | -195.88% |
| 2014 Q3 | 1.45 Billion KRW | 12.22% |
| 2014 Q2 | 1.29 Billion KRW | -0.61% |
| 2014 Q4 | 2.18 Billion KRW | 49.8% |
| 2014 Q1 | 1.3 Billion KRW | -18.05% |
| 2014 FY | - KRW | -16.44% |
| 2013 Q3 | 1.57 Billion KRW | -42.47% |
| 2013 FY | - KRW | 703.78% |
| 2013 Q2 | 2.73 Billion KRW | 55.2% |
| 2013 Q4 | 1.59 Billion KRW | 1.56% |
| 2013 Q1 | 1.75 Billion KRW | 687.25% |
| 2012 Q1 | 2.85 Billion KRW | 0.0% |
| 2012 FY | - KRW | -109.55% |
| 2012 Q2 | -4.23 Billion KRW | -247.99% |
| 2012 Q3 | -670.64 Million KRW | 84.15% |
| 2012 Q4 | 223.49 Million KRW | 133.33% |
| 2011 Q1 | 5.28 Billion KRW | 0.0% |
| 2011 Q3 | 2.76 Billion KRW | -33.97% |
| 2011 FY | - KRW | 6.3% |
| 2011 Q4 | - KRW | -100.0% |
| 2011 Q2 | 4.18 Billion KRW | -20.82% |
| 2010 Q1 | 1.79 Billion KRW | 0.0% |
| 2010 Q3 | 2.45 Billion KRW | -39.8% |
| 2010 FY | - KRW | 25.93% |
| 2010 Q4 | - KRW | -100.0% |
| 2010 Q2 | 4.07 Billion KRW | 127.62% |
| 2009 Q3 | 2.44 Billion KRW | 8.87% |
| 2009 Q4 | - KRW | -100.0% |
| 2009 FY | - KRW | 6.37% |
| 2009 Q1 | 2.5 Billion KRW | -16.99% |
| 2009 Q2 | 2.24 Billion KRW | -10.59% |
| 2008 Q3 | -806.95 Million KRW | -122.54% |
| 2008 Q4 | 3.02 Billion KRW | 474.26% |
| 2008 Q2 | 3.58 Billion KRW | 0.0% |
| 2008 FY | - KRW | -12.38% |
| 2007 FY | - KRW | 0.0% |
| Name | EBITDA | EBITDA Difference |
|---|---|---|
| Yuyu Pharma, Inc. | 4.85 Billion KRW | 6.832% |
| Dong-A Socio Holdings Co., Ltd. | 141.36 Billion KRW | 96.798% |
| Ildong Holdings Co., Ltd. | -64.03 Billion KRW | 107.069% |
| HANDOK Inc. | 35.06 Billion KRW | 87.092% |
| Kukje Pharma Co., Ltd. | -1.03 Billion KRW | 536.669% |
| Yuhan Corporation | 127.43 Billion KRW | 96.448% |
| Dong-A ST Co., Ltd. | 37.52 Billion KRW | 87.936% |
| SAMSUNG PHARM. Co., LTD. | -21.68 Billion KRW | 120.871% |
| Hanmi Pharm. Co., Ltd. | 323.33 Billion KRW | 98.6% |
| Hanall Biopharma Co.,Ltd | 4.99 Billion KRW | 9.296% |
| Ilyang Pharmaceutical Co.,Ltd | 15.11 Billion KRW | 70.06% |
| Dong Sung Bio Pharm.Co.,Ltd. | 3.42 Billion KRW | -32.313% |
| Hana Pharm Co., Ltd. | 35.48 Billion KRW | 87.245% |
| Yuyu Pharma, Inc. | 4.85 Billion KRW | 6.832% |
| Ilsung Pharmaceuticals Co., Ltd. | -18.47 Billion KRW | 124.504% |
| REYON Pharmaceutical Co., Ltd. | 6.55 Billion KRW | 30.947% |
| Aprogen pharmaceuticals,Inc. | -49.29 Billion KRW | 109.183% |
| JW Holdings Corporation | 187.88 Billion KRW | 97.591% |
| Ildong Pharmaceutical Co., Ltd. | -51.22 Billion KRW | 108.836% |
| Chong Kun Dang Pharmaceutical Corp. | 283.62 Billion KRW | 98.404% |
| JW Pharmaceutical Corporation | 89.22 Billion KRW | 94.927% |
| Shin Poong Pharm.Co.,Ltd. | -37.06 Billion KRW | 112.211% |
| Hyundai Pharmaceutical Co., Ltd. | 13.2 Billion KRW | 65.734% |
| Samil Pharmaceutical Co.,Ltd | 11.82 Billion KRW | 61.731% |
| Jeil Pharmaceutical Co.,Ltd | 18.65 Billion KRW | 75.736% |
| Yuyu Pharma, Inc. | 4.85 Billion KRW | 6.832% |
| Kwang Dong Pharmaceutical Co., Ltd. | 54.97 Billion KRW | 91.766% |
| Daewoong pharmaceutical Co.,Ltd | 164.91 Billion KRW | 97.255% |
| JW Pharmaceutical Corporation | 89.22 Billion KRW | 94.927% |
| Yuhan Corporation | 127.43 Billion KRW | 96.448% |
| Jeil Pharma Holdings Inc | 33.47 Billion KRW | 86.479% |
| Yungjin Pharm. Co., Ltd. | 7.64 Billion KRW | 40.83% |
| Suheung Co., Ltd. | 77.02 Billion KRW | 94.124% |
| JW Pharmaceutical Corporation | 89.22 Billion KRW | 94.927% |
| Samjin Pharmaceuticals Co., Ltd. | 36.63 Billion KRW | 87.644% |
| Korea United Pharm Inc. | 70.78 Billion KRW | 93.605% |
| CKD Bio Corp. | -1.63 Billion KRW | 377.618% |
| Daewon Pharmaceutical Co., Ltd. | 49.79 Billion KRW | 90.91% |
| Dongwha Pharm.Co.,Ltd | 32.56 Billion KRW | 86.099% |
| Whan In Pharm Co.,Ltd. | 36.81 Billion KRW | 87.703% |
| Shin Poong Pharm.Co.,Ltd. | -37.06 Billion KRW | 112.211% |
| Chong Kun Dang Holdings Corp. | 62.28 Billion KRW | 92.733% |
| Boryung Corporation | 114.28 Billion KRW | 96.039% |
| Bukwang Pharmaceutical Co., Ltd. | -30.56 Billion KRW | 114.808% |
| Ilyang Pharmaceutical Co.,Ltd | 15.11 Billion KRW | 70.06% |
| JW Lifescience Corporation | 50.82 Billion KRW | 91.095% |